Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

AML At First Relapse: A Real Life Picture

Eileen Mary Boyle, MD, Claude Preudhomme, MD, PhD, Olivier Nibourel, Catherine Roche-Lestienne, PhD, Gareth J Morgan, MD PhD, Brigitte Dupriez, MD, Isabelle Plantier, MD, Berengere Gruson, MD, Jean Pierre Marolleau, MD, PhD, Delphine Lebon, MD, Jose Fernandes, MD, Christophe Willekens, Bruno Quesnel, MD, PhD, Céline Berthon, MD, PhD

Blood (2013) 122 (21): 3895.

https://doi.org/10.1182/blood.V122.21.3895.3895

Published: 2013

Journal Articles

Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group

Blood (2010) 116 (21): 4171.

https://doi.org/10.1182/blood.V116.21.4171.4171

Published: 2010

Journal Articles

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Blood (2010) 116 (21): 3410.

https://doi.org/10.1182/blood.V116.21.3410.3410

Published: 2010

Journal Articles

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

Blood (2008) 112 (11): 183.

https://doi.org/10.1182/blood.V112.11.183.183

Published: 2008

Journal Articles

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Catherine Roche-Lestienne, PhD, Laureline Deluche, MD, Selim Corm, MD, Isabelle Tigaud, MD, Sami Joha, PhD, Nathalie Philippe, PhD, Sandrine Geffroy, PhD, Jean-Luc Lai, PhD, Franck Nicolini, MD, PhD, Claude Preudhomme, MD, PhD

Blood (2007) 110 (11): 2786.

https://doi.org/10.1182/blood.V110.11.2786.2786

Published: 2007

Journal Articles

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

Franck E. Nicolini, MD, PhD, Emmanuel Bachy, MD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Dominique Bories, MD, PhD, Michel Tulliez, MD, Nathalie Sorel, MD, Francois Guilhot, MD, Laurence Legros, MD, François-Xavier Mahon, MD, PhD, Frédéric Maloisel, MD, Jean-Jacques Kiladjian, MD, PhD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2006) 108 (11): 2190.

https://doi.org/10.1182/blood.V108.11.2190.2190

Published: 2006

Journal Articles

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Franck E. Nicolini, MD, PhD, Sélim Corm, MD, Quoc-Hung Lê, MD, Sandrine Hayette, PhD, Nathalie Sorel, PhD, Dominique Bories, MD, PhD, Stéphane Giraudier, MD, PhD, Michel Tulliez, MD, Philippe Rousselot, MD, Jean-Michel Cayuela, MD, François-Xavier Mahon, MD, PhD, Pascale Cony-Makhoul, MD, Jean-Jacques Kiladjian, MD, Olivier Tournilhac, MD, François Guilhot, MD, Catherine Roche-Lestienne, PhD, Claude Preudhomme, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2005) 106 (11): 3284.

https://doi.org/10.1182/blood.V106.11.3284.3284

Published: 2005

Journal Articles

Molecular Characterization of the Idiopathic Hypereosinophilic Syndrome (HES) in 35 French Patients with Normal Conventional Cytogenetics.

Catherine Roche-Lestienne, PhD, Valerie Soenen-Cornu, MD, PhD, Jean-Emmanuel Kahn, MD, Jean-Luc Lai, PhD, Eric Hachulla, MD, Francois Drupt, MD, Anne-Laure Demarty, MD, Martine Gardembas, MD, Nathalie Philippe, Stephane Barette, MD, Christian Libersa, MD, PhD, Olivier Bletry, MD, PhD, Christian Rose, MD, PhD, Pierre Fenaux, MD, PhD, Lionel Prin, MD, PhD, Claude Preudhomme, MD, PhD

Blood (2004) 104 (11): 2442.

https://doi.org/10.1182/blood.V104.11.2442.2442

Published: 2004

Journal Articles

Mutation Status of Imatinib Mesylate-Resistants CML Patients and Clinical Outcomes: A French Multicenter Retrospective Study for the fiLMC Group.

Selim Corm, MD, Franck Nicollini, MD, Dominique Borie, MD, Nathalie Sorel, MD, Thibault Leguay, MD, Sandrine Hayette, PhD, Thierry Facon, MD, PhD, Laurence Roy, MD, Stephane Giraudier, MD, PhD, Gerald Marit, MD, Claude Preudhomme, MD, PhD, Mauricette Michalet, MD, PhD, Francois-Xavier Mahon, MD, PhD, Michel Thuilliez, MD, PhD, Francois Guilhot, MD, PhD, Catherine Roche-Lestienne, PhD

Blood (2004) 104 (11): 275.

https://doi.org/10.1182/blood.V104.11.275.275

Published: 2004

NARROW

AML At First Relapse: A Real Life Picture

Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group

The Presence of the BCR-ABL T315I Mutation In Chronic Phase Chronic Myelogenous Leukemia Resistant to Tyrosine Kinase Inhibitors Profoundly Compromises Overall Survival and Progression Free Survival. Preliminary Results of a Matched Pair Analysis.

Randomized Comparison of Imatinib Versus Imatinib Combination Therapies in Newly Diagnosed Chronic Myeloid Leukaemia (CML) Patients in Chronic Phase (CP): First Results of the Phase III (SPIRIT) Trial from the French CML Group (FI LMC)

RUNX1 DNA-Binding Mutations and RUNX1-PRDM16 Cryptic Fusion in BCR/ABL+ Leukemias Are Frequently Associated with Secondary Trisomy 21 and May Contribute to Clonal Evolution and Imatinib Resistance.

Clinical Outcome of 27 Imatinib Mesylate Resistant Chronic Myelogenous Leukemia (CML) Patients Harbouring a T315I BCR-ABL Mutation.

P-Loop an T315I BCR-ABL Mutations in Chronic Myelogenous Leukemia (CML) Patients Are of Poor Prognosis, but the Y253H + E255K P-Loop Mutations Are of Even More Severe Prognosis in Chronic Phase. On the Behalf of the French Intergroup of CML (Fi-LMC Group).

Molecular Characterization of the Idiopathic Hypereosinophilic Syndrome (HES) in 35 French Patients with Normal Conventional Cytogenetics.

Mutation Status of Imatinib Mesylate-Resistants CML Patients and Clinical Outcomes: A French Multicenter Retrospective Study for the fiLMC Group.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only